The companies first announced their partnership in 2015 and in November last year the pair won 510(k) clearance from the FDA to market the Propeller plaftform with the Ellipta dry powder inhaler.
Propeller and GSK added that they plan to continue ongoing R&D efforts together, studying the connected inhaler in combination with GSK’s repsiratory drugs for asthma and chronic obstructive pulmonary disease.
“We are excited to be working closely with GSK to make the sensor for the Ellipta inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the US,” Propeller CEO & co-founder David Van Sickle said in prepared remarks. “Companion digital experiences simplify and personalize the management of chronic respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines.”
“Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition,” senior VP & head of GSK’s global respiratory franchise, Eric Dube, added. “We are excited to expand our collaboration with Propeller as a further step in our journey towards achieving connected health systems for people with asthma and COPD.”